Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb, with a price target of $60.00. Bansal c...

Bristol-Myers Squibb (BMY) Receives a Hold from Wells Fargo

Markets React to Oil, Risk, and Rotation U.S. stocks moved lower last week as war risk and rising oil prices weighed on sentiment. The S&P 500 (SPX...

The Week That Was, The Week Ahead: Macro and Markets, Mar. 29

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb Co. (BMY) is running a Phase 1 study ...

Bristol-Myers Squibb Advances BMS-986278 Through Key Heart Safety Study

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb (BMY) is running a real-world chart r...

BMY Targets Real-World Edge for Ozanimod in Ulcerative Colitis

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Korro Bio (KRRO – Research Report), Sagimet Biosci...

Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. The Bristol-Myers Squibb study “Effectiveness and Adverse-...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMY	$59.60	0.00%	14.75M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMY	$59.60	0%	14.75M
3
4
5
6

BMY

BMY

Get Bristol-Myers Squibb Company Data in Excel

Get Bristol-Myers Squibb Company Data in Excel